Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822525 | 0.80 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL9312689 | 0.80 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL8466217 | 0.79 | CFTR (0.52) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| Hydrochloric Acid SCHEMBL15547862 | 0.78 | CFTR (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| Hydrochloric Acid SCHEMBL9671497 | 0.78 | CFTR (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1985149 | 0.78 | CFTR (0.50) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1455475 | 0.77 | — | — | |
| SCHEMBL1266179 | 0.77 | — | — | |
| SCHEMBL222775 | 0.77 | — | — | |
| SCHEMBL29668672 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111163761-A | Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide | 普梭梅根公司 | 2020-05-15 | — | — | CN | claimed |
| CN-111163761-A | Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide | 普梭梅根公司 | 2020-05-15 | — | — | CN | disclosed |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| EP-0900207-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1129075-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027820-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
| CN-1222909-A | Pyrazinone thrombin inhibitors | MERCK & CO INC (US) | 1999-07-14 | — | — | CN | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | CFTR 1779/4885SLC6A2 3091/4885SLC6A4 2839/4885 |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NR2E3, AXL, FLT1 | CFTR 1313/4885SLC6A2 3391/4885SLC6A4 2970/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | CFTR 1671/4885SLC6A2 3058/4885SLC6A4 2827/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | CFTR 1753/4885SLC6A2 3045/4885SLC6A4 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.